Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial
EClinicalMedicine2021Vol. 38, pp. 101010–101010
Citations Over TimeTop 10% of 2021 papers
Wanshen Guo, Kai Duan, Yuntao Zhang, Zhiming Yuan, Yanbo Zhang, Zejun Wang, Dongyang Zhao, Huajun Zhang, Zhiqiang Xie, Xinguo Li, Peng Cheng, Wei Zhang, Yunkai Yang, Wei Chen, Xiaoxiao Gao, Wangyang You, Xuewei Wang, Zheng‐Li Shi, Yanxia Wang, Xuqin Yang, Lianghao Zhang, Lili Huang, Qian Wang, Jia Lu, Yongli Yang, Jing Guo, Wei Zhou, Xin Wan, Cong Wu, Wenhui Wang, Jianhui Du, Xuanxuan Nian, Xinghang Li, Shihe Huang, Shuo Shen, Shengli Xia, An Pan, Xiaoming Yang
Abstract
The inactivated vaccine against COVID-19 was well tolerated and immunogenic in both younger and older adults. The two-dose schedule of 5 µg on days 0 and 21/28 and three-dose schedules on days 0, 28, and 56 could be further evaluated for long-term safety and efficacy in the phase 3 trials.
Related Papers
- → Enhancement of immunogenicity and neutralizing responses against SARS-CoV-2 spike protein using the Fc fusion fragment(2023)9 cited
- → Effect of tailored information of vaccination schedule on vaccine uptake in northern Nigeria(2021)4 cited
- → Reasons of the delayed vaccination, recommendations and safety of vaccination in children with congenital heart disease in Zhejiang, China(2021)9 cited
- → Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers(1990)85 cited
- → [Preparation and immunogenicity evaluation of mRNA vaccine against porcine epidemic diarrhea].(2023)4 cited